From Medscape Oncology

Coverage from the

European Hematology Association (EHA) 2016 Congress

June 09 - 12, 2016; Copenhagen, Denmark

June 09 - 12, 2016 Copenhagen, Denmark
  • Blinatumomab Beats Chemo for R/R ALL: Survival Doubled The single-agent immunotherapy was superior to chemotherapy in relapsed/refractory acute lymphoblastic leukemia, almost doubling overall survival in the phase 3 TOWER trial.
  • EHA CAR T Cells Effective in Advanced Lymphoma The CAR T-cell approach shows encouraging rates of complete responders even when preceded with low-dose chemotherapy, and 'troublesome' neurotoxic adverse events typically resolve within days.
  • EHA Latest Daratumumab Results Herald 'New Era' in Myeloma Another daratumumab trial shows benefit in relapsed myeloma, with the highest response rates ever seen; the findings herald a 'new era of immunotherapies,' says expert.

Conference News

Medscape Oncology©  WebMD, LLC

Previous Coverage